RT @EHF_Official: Monthly and quarterly fremanezumab significantly reduced the monthly average number of migraine days versus placebo in mi…
703 followers
2,990 followers
Monthly and quarterly fremanezumab significantly reduced the monthly average number of migraine days versus placebo in migraine patients with documented inadequate response to 2 to 4 migraine preventive medication classes. https://t.co/SQJ1SjG7Ek #migrain
1,651 followers
Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial https://t.co/cnJG263PZl